Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Line of Credit

Note 5 - Line of Credit
3 Months Ended
Mar. 31, 2021
Line of Credit Facility [Abstract]  
Line of Credit

On November 8, 2010, the Company entered into a financing arrangement with Gemini Pharmaceuticals, Inc., a product development and manufacturing partner of the Company, pursuant to which Gemini Pharmaceuticals made a $250,000 strategic equity investment in the Company and agreed to make a $750,000 purchase order line of credit facility available to the Company. The outstanding principal of all advances under the line of credit will bear interest at the rate of interest of prime plus 2% per annum.


As of March 31, 2021 and December 31, 2020, outstanding balance of this credit line amounted to $31,000, respectively.